Dr. George Chris Canas, MD

Dr. Canas practices at Faribault Dialysis Unit in Minneapolis, Minnesota.

Dr. Canas' NPI, 1922025774, was assigned on July 17, 2006. Dr. Canas graduated from University of Minnesota Medical School in 1998. Dr. Canas holds Minnesota license 42157.

Dr. Canas' primary practice is Faribault Dialysis Unit, at 6200 Shingle Creek Pkwy, Minneapolis, MN 55430 in Hennepin County. The practice phone is (507) 334-0306.

Dr. Canas' primary practice is Faribault Dialysis Unit in Minneapolis, Minnesota. Dr. Canas is also affiliated with Abbott Northwestern Hospital. The medical group on file is Buffalo Hospital. Dmand AI also links Dr. Canas to 2 more hospitals, 3 dialysis centers, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Canas practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Canas' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Canas is licensed in Minnesota.

CMS data shows 1,069 Medicare services from Dr. Canas across 10 procedure codes in 2024, for 344 Medicare patients. Medicare paid $114,087 for them.

CMS counts 344 Medicare patients who saw Dr. Canas in 2024. The largest group is 75 to 84, with 115 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 4.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Canas' median patient age at 70, with 50% women.

In 2024, Dr. Canas wrote 1,256 Medicare Part D claims for 194 patients. 89% of them were for generic drugs. CMS names the drug for 1,012 of them, across 29 drugs with 11 or more claims each, at $123,140 in total drug cost. In 2023, CMS named 876 claims across 29 drugs.

Dr. Canas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Canas as offering telehealth.

Dmand AI links 2 papers to Dr. Canas in 2022. Dr. Canas has published most often in Eur J Drug Metab Pharmacokinet. Dr. Canas' most frequent co-author is Peter John Winkle, MD.

Dmand AI links Dr. Canas to 2 clinical trials, 2 of them phase 1 studies. Conditions studied include Renal Insufficiency, Renal Insufficiency, Chronic and Kidney Diseases.

CMS Open Payments shows 8 general payments to Dr. Canas from 3 drug and device companies from 2016 to 2025. Education make up the largest share, 76% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $202. It also lists 3 research payments totaling $1,943 from 2021 to 2022.

Dr. Canas graduated from University of Minnesota Medical School in 1998.